Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a diabetes drug calm inflammation after heart stenting?

NCT ID NCT07292909

First seen Jan 04, 2026 · Last updated May 25, 2026 · Updated 20 times

Summary

This study looks at whether empagliflozin, a diabetes drug, can lower inflammation after a heart stent procedure. About 100 people with stable coronary artery disease will take either empagliflozin or a placebo for three days before their scheduled stent placement. Researchers will measure C-reactive protein (a marker of inflammation) before and 24 hours after the procedure to see if the drug reduces the expected rise in inflammation.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SGLT 2 INHIBITORS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hotel Dieu de France

    RECRUITING

    Beirut, Beirut, 00000, Lebanon

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.